Cutaneous T-cell lymphoma-associated antigen 1 (CTAGE1)

Cutaneous T-cell lymphoma-associated antigen 1 (CTAGE1) is a member of the cancer/testis antigen family—genes normally expressed in testicular germ cells but aberrantly activated in certain cancers, including CTCL, melanoma, breast, colon, and head/neck carcinomas[2][3][4][6]. CTAGE1 has several splicing variants and is robustly and uniformly expressed in CTCL lesion skin and cell lines, but not in normal skin or benign inflammatory dermatoses[4]. Its expression can be upregulated by histone deacetylase inhibitors and is regulated by epigenetic mechanisms[4]. CTAGE1 is immunogenic in cancer patients, eliciting antibody responses specific to tumor tissue, and its presence is considered a promising target for immunotherapy and a biomarker for disease progression in CTCL and other malignancies[3][4]. Therapeutic exploitation is ongoing, but concerns typical of cancer/testis antigens (heterogeneous tumor expression and off-tumor risks) remain and require further study[2][4]. No evidence from available search results suggests CTAGE1 is a receptor, enzyme, transporter, or transcription factor; it is best classified as a tumor-associated antigen within the cancer/testis antigen molecular family[2][3][4][6]. No approved drugs directly target CTAGE1 beyond indirect effects from epigenetic modulators, and it remains a candidate for cancer immunotherapy and biomarker development.

Other names

CTAGE1CTAGE-1cTAGE-1CTAGE2cTAGE-2Protein cTAGE-1Protein cTAGE-2CT21.1CT21.2Cancer/testis antigen 21.1Cancer/testis antigen 21.2cTAGE family member 2

Epigenetic modulation (Histone deacetylase inhibitor drugs upregulate CTAGE1 expression, putatively through alteration of DNA/histone methylation); Immunogenic recognition (immunotherapy focuses on CTAGE1 as a tumor antigen, enabling T-cell targeting of CTCL cells)